Health and Fitness Club Industry News: Other News
Sunday, September 24th, 2023
ALS TDI Awarded CDC Funding to Accelerate Identification of ALS Risk Factors
Posted: August 29, 2023 in Other News
CAMBRIDGE, MA - The ALS Therapy Development Institute (ALS TDI) announces a significant development in its pursuit of ALS insights. ALS TDI has received a substantial grant from the Centers for Disease Control and Prevention (CDC), $480,000 annually for up to three years, to initiate a comprehensive research project dedicated to identifying the lifestyle risk factors associated with ALS. Read More...
May is ALS Awareness Month
Posted: May 9, 2023 in Other News
DENVER, CO - ALS Awareness month is a time for members of this important community to tell their stories and the importance of finding a cure for ALS. You can make a difference this May by raising awareness for Augie's Quest in several ways. Please consider some simple actions that have a huge impact! Here are 5 Ways to Raise Awareness for the ALS Community... Read More...
Augie’s Quest Raises More Than $300,000 at IHRSA 2023
Posted: March 24, 2023 in Suppliers
SAN DIEGO, CA - Augie’s Quest kicked off the week at IHRSA by celebrating Augie with some of our key supporters and friends from the health and fitness industry. A special thanks to our friends at Bay Club and Zumba for making Augie’s Celebration a success! Augie's Quest received over $300,000 from the health and fitness industry, helping it continue Augie’s legacy! Read More...
Augie Nieto Dies at Age 65 – Fitness Industry Mogul, Founder of Augie’s Quest to Cure ALS & Hero to ALS Families
Posted: February 24, 2023 in Other News
ORANGE COUNTY, CA - With deep sadness, Augie’s Quest shares the news that its Founder, Beloved Leader and ALS Champion, Augie Nieto, died, surrounded by his family on February 22, 2023, just seven days past his 65th Birthday. Augie was the fitness industry mogul credited for the success of Lifecycle, Life Fitness and Octane Fitness brands. In 2005, at the height of his career, he was diagnosed with amyotrophic lateral sclerosis, or ALS, a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. Read More...
Racing for ALS Celebrates a Big 2022, and Bigger Things to Come in 2023
Posted: December 23, 2022 in Other News
CAMBRIDGE, MA - Racing for ALS had a big 2022, and they’re looking forward to an even bigger 2023. The organization, which rallies auto racing fans across the country to support the fight against ALS, raised more than $700,000 to support ALS research and services this past year. They accomplished this through a series of high-performance driving events, as well as supplementary fundraisers and individual donations from their supporters. Read More...
2022 ALS TDI Summit Presents Updates on Promising Research and Potential Treatments
Posted: October 21, 2022 in Other News
CAMBRIDGE, MA - On October 14, 2022, ALS Therapy Development Institute (ALS TDI) scientists and guest presenters from across the ALS space gathered at the ALS TDI Summit in Boston, to provide the community with updates on research from the past year. They were joined by an audience from across the ALS community, including people with ALS, families, advocates, researchers, pharmaceutical industry professionals and many more who streamed the event online. Read More...
ALS TDI’s 2022 Mid-Year Highlights
Posted: August 17, 2022 in Other News
CAMBRIDGE, MA - Ending ALS will require many treatments to meet the needs of every individual with this disease. As the Drug Discovery Engine for ALS, ALS TDI is solely focused on inventing and discovering treatments until everyone with ALS has access to effective therapies. ALS TDI is proud of the progress that it has made thus far in 2022 and looks forward to continuing to share detailed updates at the 2022 ALS TDI Summit on October 14th. Here are some of our research highlights so far in 2022.... Read More...
Move In May for ALS Awareness Month
Posted: April 18, 2022 in Other News
If you have ever run a race, you know how amazing it feels when you cross that finish line. As a current or future ALS Supporter, it is hoped that you know how crucial funding is to move ALS treatments forward. That's why Augie's Quest hopes you'll the Virtual Race to Cure ALS in honor of May ALS Awareness Month. Choose the activity of your choice! Run, walk, hike or bike any distance, anywhere, anytime between May 22 - 28 and raise critical funds and awareness for ALS. Register Today to Move In May! Read More...
2021 ALS TDI Summit Presents Potential Treatments and Innovative New Technology
Posted: November 17, 2021 in Other News
WATERTOWN, MA - Every year, the ALS Therapy Development Institute (ALS TDI) hosts the ALS TDI Summit as a way to update its community on the state of ALS research and drug discovery at ALS TDI. The Summit program included updates about drug discovery research programs in various stages of development at ALS TDI, as well as an extensive update on Project Euphonia, an initiative from Google to develop communication tools for people with conditions that affect their speech like ALS that was launched in collaboration with ALS TDI. ALS TDI also paid tribute to outstanding members of the ALS community with the annual Leadership Awards. Read More...
Augie’s Quest and Myzone 2021 MEPS Challenge
Posted: October 24, 2021 in Other News, Suppliers
DENVER, CO and U.K. - Myzone is again linking up with Augie's Quest for a special 45-day Augie’s Quest Challenge for your club’s staffs that starts on November 1. The Challenge is a fundraiser for Augie’s Quest, and you can easily enter a team of seven staff to compete in this national challenge for a total donation of $349. Read More...
Phase 2 Trial of ALS TDI-Invented AT-1501 Almost Fully Enrolled
Posted: September 9, 2021 in Other News
CAMBRIDGE, MA - A phase 2 trial of AT-1501, a potential ALS treatment invented the ALS Therapy Development Institute (ALS TDI), is almost fully enrolled according to its current sponsor, Eledon Pharmaceuticals. AT-1501 (antiCD40L) is an antibody therapeutic with comprehensive and promising preclinical data. It blocks specific immune cell activation and protects nerves against the progression of ALS and Alzheimer's disease. It is the first potential ALS treatment to be invented by a nonprofit biotech and advanced into human clinical trials. Read More...
Raising ALS Awareness Around the World on International ALS/MND Day
Posted: June 21, 2021 in Other News
CAMBRIDGE, MA - In America, we work to spread awareness of Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s Disease, for the entire month of May as part National ALS Awareness Month. However, there is also one single day when the entire world comes together to share the story of this devastating disease, as well as the global effort to both find treatments for it and support those living with ALS. Read More...
Join Augie’s Quest for ALS Awareness Month
Posted: May 4, 2021 in Other News
May is ALS Awareness Month. In May alone, 496 people will be diagnosed with ALS and will be challenged to choose how they spend their remaining years. Every day, Augie Nieto chooses to celebrate and focus on what he can do rather than what he can’t. He has shifted from finding fitness solutions to improve lives to finding a cure to save lives, and he’s still keeping busy, working to achieve that goal. Read More...
ALS TDI Honors Community Members with 2020 ALS Leadership Awards
Posted: November 23, 2020 in Other News
CAMBRIDGE, MA - 2020 has been a year unlike any other. Facing a global pandemic, economic uncertainty, and the realities of lockdowns, quarantines and social distancing, the ALS community still found many creative ways to stay strong and united, even from afar. The support of this community has been incredibly important to keeping research to end Amyotrophic Lateral Sclerosis (ALS) at the ALS Therapy Development Institute (ALS TDI) going, despite the many challenges we’ve all faced this year. Read More...
Novus Therapeutics Announces Enrollment of First ALS Patient in Phase 2 Trials of AT-1501, A Drug Invented at ALS-TDI
Posted: November 2, 2020 in Other News
CAMBRIDGE, MA - The ALS Therapy Development Institute (ALS TDI) is excited to share a significant step in the advancement of AT-1501, a drug invented at ALS TDI, as a potential treatment for people with amyotrophic lateral sclerosis (ALS). Novus Therapeutics, Inc., a clinical stage biopharmaceutical company, has announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501 in adults. Read More...
How to Advance ALS TDI’s Latest Discovery in the Lab
Posted: September 30, 2020 in Other News
CAMBRIDGE, MA - The ALS Therapy Development Institute (ALS TDI) recently announced the discovery of a new drug target, Type I PRMTs, for ALS caused by the C9orf72 mutation. We were excited to share those recent findings with the broader ALS research community and with you. We remain in the early days with this discovery, but we are optimistic as we take steps to further advance our findings. Because we can’t complete all of these steps alone, we are developing partnerships to make progress against each of these objectives. However, that progress won’t be possible without the continued support from the ALS community. Read More...
How ALS TDI is Moving Forward with Phase 1 Reopening of Lab
Posted: June 1, 2020 in Other News
CAMBRIDGE, MA - ALS TDI’s Chief Scientific Officer Fernando Vieira, M.D., talks about how ALS TDI is allowing more scientists to enter the lab in accordance with Massachusetts Phase 1 reopening guidelines. ALS TDI thank you for support over the last few months, which has allowed us to maintain the pace of promising ALS research amidst the COVID-19 pandemic. This first week of June, in accordance with the Massachusetts phased reopening guidelines, ALS TDI began allowing more of our scientists and researchers to return to the Cambridge-based lab. While pleased to be able to resume additional operations the safety of staff remains a top priority. Read More...
ALS TDI Study Uncovers New Clue as to Why C9or72 Mutations May Cause Neurodegenerative Disease
Posted: April 17, 2020 in Other News
CAMBRIDGE, MA - It is known that C9orf72 repeat expansion mutations are the most common cause of ALS, but the mechanisms of how and why it causes the disease remain, for the most part, a mystery. However, a new paper by ALS Therapy Development Institute (ALS TDI) scientist, Anna Gill, and several collaborators, may have a promising new clue as to why these C9orf72 mutations may be particularly toxic for brain cells. Read More...
Why COVID-19 Treatments May be Coming in Months, While ALS Research Takes Years
Posted: March 19, 2020 in Other News
CAMBRIDGE, MA - For those who have been waiting years, even decades, for a cure for a disease like ALS, it can be both hopeful and frustrating to hear about the possible rapid development of treatments for COVID-19. Assuming that an effective treatment can be found, there are many reasons why a treatment for an infectious disease like COVID-19 might be easier to develop than one for a condition like ALS. Read More...
Augie’s Quest 15th Annual BASH Event Returns to San Diego
Posted: February 7, 2020 in Other News
SAN DIEGO, CA - Augie’s Quest to Cure ALS, a nonprofit committed to changing the experience of thousands living with amyotrophic lateral sclerosis (ALS) by fast-tracking effective treatments and an ultimate cure, is celebrating their 15th BASH fundraiser by Rockin’ Through the Ages with the fitness industry on March 20. Over 800 guests are expected to attend the event, which is held in conjunction with the International Health, Racquet and Sportsclub Association’s (IHRSA) International Tradeshow and Convention. The BASH represents an opportunity for the fitness industry to come together and celebrate advancements in ALS research, while reminding attendees of the critical hope their support offers for those affected by this disease. Read More...
